Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center.
Ipsen SA and Biomunex Pharmaceuticals SAS have signed an exclusive global licensing agreement for BMX-502, a preclinical novel T-cell engager with potential for solid tumors. BMX-502 is a bispecific antibody that engages and activates mucosal-associated invariant T (MAIT) cells and targets the GPC3 tumor antigen, to kill cancer cells.
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs).
There is increasing interest in developing precision immunotherapies that target tumors but with minimal impact on healthy tissues. IL-12 is a potent immunostimulatory cytokine that has shown effective antitumoral activity in the preclinical setting, but its systemic delivery may be accompanied by off-target effects.
Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities underscore the need for new therapeutic strategies.
Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to selectively deliver IL-21 to PD-1-expressing cells for the treatment of cancer.
AGEN-1721 was designed as an Fc-enhanced bifunctional antibody to selectively target FAP and neutralize TGF-β via an optimized TGF-βR2 TRAP moiety fused to an engineered Fc region, with the aim of maximizing effector functions.
Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.
RSS
